Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Net Margin (2018 - 2025)

Dna X's Net Margin history spans 8 years, with the latest figure at 29.31% for Q3 2025.

  • Quarterly results put Net Margin at 29.31% for Q3 2025, down 1259.0% from a year ago — trailing twelve months through Dec 2025 was 18.85% (down 1412.0% YoY), and the annual figure for FY2024 was 52.77%, down 5320.0%.
  • Net Margin for Q3 2025 was 29.31% at Dna X, up from 66.8% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 39.37% in Q4 2024 to a low of 75.82% in Q1 2021.
  • The 5-year median for Net Margin is 17.32% (2024), against an average of 27.9%.
  • The sharpest move saw Net Margin skyrocketed 6926bps in 2022, then tumbled -5935bps in 2024.
  • Year by year, Net Margin stood at 73.58% in 2021, then surged by 94bps to 4.32% in 2022, then plummeted by -49bps to 6.42% in 2023, then skyrocketed by 713bps to 39.37% in 2024, then crashed by -174bps to 29.31% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 29.31%, 66.8%, and 2.74% for Q3 2025, Q2 2025, and Q1 2025 respectively.